Reckitt's Like-for-Like Revenue Rises on Emerging Markets Performance
By Aimee Look
Lysol maker Reckitt Benckiser booked a rise in first-quarter like for like revenue, helped by strong emerging markets growth, though a weak cold-and-flu season in Europe hurt performance.
The British consumer goods giant, which also makes Durex condoms and Mucinex cold medicine, said Wednesday that like-for-like net revenue grew 0.6%.
However, on a reported basis, net revenue was 3.25 billion pounds ($4.39 billion) for the first quarter, compared with 3.68 billion pounds the year prior.
Company-compiled analysts' estimates expected 3.19 billion pounds in reported net revenue for the first quarter, and 1.6% like-for-like growth.
Reckitt said a weak cold-and-flu season caused a decline in net revenue in Europe, following a previous warning that there would be continued challenges with trading in the region. Like-for-like net revenue in Europe declined 4.2% for the quarter, and its over-the-counter business like-for-like sales had a double-digit decline.
Meanwhile, Reckitt's emerging markets like-for-like sales grew 7.6%.
Write to Aimee Look at aimee.look@wsj.com
(END) Dow Jones Newswires
April 22, 2026 02:55 ET (06:55 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States